Strategic collaboration for the development of LRRK2 kinase inhibitors in Parkinson’s disease. Servier to be granted option to exclusively license one or several drug candidates as soon as they are approved to enter phase 1. Servier will fund entire program. Oncodesign will receive an upfront payment of €3M at the signing of the partnership, and […]
Press Release : Servier and OSE Immunotherapeutics* announced the first step under a two-step option agreement for exclusive global rights to OSE-127. OSE-127 is a differentiated monoclonal antibody antagonist targeting the interleukin-7 receptor (IL-7R), discovered by OSE, for the treatment of auto-immune diseases and chronic inflammation. Under the license agreement, exercising the first step of […]
February 4th is world cancer day, Every day, Every day, Servier strongly supports the global research effort by making oncology a priority therapeutic research area. Our R&D programs are exploring two tracks: therapies aimed at the restoration of programmed cell death (apoptosis) in cancer cells, and mobilizing the immune system (immuno-oncology). Innovation in oncology also […]
Sales of €4.2 billion and 4.5% growth at constant exchange rate that confirm the increase in the number of patients treated with our drugs worldwide. Servier’s sales comprise €2.9 billion for brand drugs (+3% at constant rate) and €1.3 billion for generic drugs (+8% at constant rate). An operating income that is 7.4% of sales […]
The GOLD journal, published by the EMG – European Medical Group – offers a major interview with our Chief Patient Officer, Lode Dewulf. He talks about the motivations that made him want to join Servier and the benefits of the Patient Value. Read the interview here: https://www.emg-gold.com/articles/companies-that-treat-their-employees-the-right-way-can-succeed-in-treating-patients-the-right-way
Parkinson’s disease: Servier and Oncodesign join forces to investigate new line of research